We appreciate the questions raised and the interpretations offered by our colleagues and respond as follows. First, we provided data on the ratio of sarcolemmal to total glucose transporter (GLUT)-4 as an accepted and standard method for establishing insulin mediated GLUT-4 translocation. There was no difference in the total GLUT-4 protein expression between control and glucagon-like peptide (GLP)-1-treated groups. Therefore, the ratio reflects insulin-mediated translocation. This is consistent with the increase in Akt-phosphorylation at both the catalytic and regulatory subunits. The ratio of p-Akt to total Akt is an established method for examining activation of Akt. There were no differences in the total protein expression of Akt as measured by Western blots between control and GLP-1-treated groups.
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We agree that the mechanisms relating to GLP-1 cellular effects are complex and may vary depending on the state of glycemia, magnitude of insulin resistance, and degree of contractile dysfunction. We have shown previously that GLP-1 has an insulinomimetic effect on myocardial glucose uptake under circumstances of euglycemia. The present study was our first attempt at chronic treatment with GLP-1 in a rodent model of hypertension, hyperglycemia, and progressive left ventricular dysfunction. Under the circumstances in vivo, there was significant hyperglycemia and consequent increases in insulin levels in response to GLP-1, consistent with an insulinotropic effect. The insulinotropic effects of GLP-1 over time were significantly greater (1736Ϯ164 to 2309Ϯ178 pmol/L) than the insulin responses seen in control (1439Ϯ189 to 1679Ϯ210 pmol/L). Unfortunately, we could not measure substrate extraction and uptake in vivo. However, myocardial samples from chronically treated rats demonstrated evidence of increased Akt phosphorylation and GLUT-4 translocation, consistent with an insulin mediated effect. These Akt-mediated effects have been seen consistently in ischemia-reperfusion experiments with GLP-1 conducted under hyperglycemic conditions. [1] [2] [3] We agree that the in vitro studies in isolated hearts suggest enhanced insulin sensitivity in these hearts after chronic treatment. However, these experimental conditions are distinct from those in vivo, particularly in glucose concentration (5 mmol/L). As such, we acknowledge that there may be other mechanisms beside Akt activation that contribute to increased glucose uptake in vitro.
We appreciate the acknowledgement of our previous work in canine experimental models where the glucoregulatory actions of GLP-1 under circumstances of euglycemia suggest insulin-independent actions. The relative contributions of insulin-dependent and -independent effects of GLP-1 on myocardial glucose uptake under conditions of hyperglycemia remain to be determined.
